WallStreetZenWallStreetZen

NASDAQ: CTOR
Citius Oncology Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CTOR

Based on 1 analyst offering 12 month price targets for Citius Oncology Inc

Min Forecast
$6.00+683.29%
Avg Forecast
$6.00+683.29%
Max Forecast
$6.00+683.29%

Should I buy or sell CTOR stock?

Based on 1 analyst offering ratings for Citius Oncology Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CTOR's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CTOR as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their CTOR stock forecasts and price targets.

CTOR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-23

1 of 1

Forecast return on equity

Is CTOR forecast to generate an efficient return?

Company
115.61%
Industry
55.72%
Market
164.8%
CTOR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CTOR forecast to generate an efficient return on assets?

Company
61.41%
Industry
17.28%
CTOR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CTOR earnings per share forecast

What is CTOR's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.19
Avg 2 year Forecast
$0.40
Avg 3 year Forecast
$0.77

CTOR revenue forecast

What is CTOR's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$39.6M+905.25%
Avg 2 year Forecast
$121.3M+2,975.98%
Avg 3 year Forecast
$160.6M+3,970.88%
CTOR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CTOR revenue growth forecast

How is CTOR forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
421.28%
Industry
8.39%
Market
15.36%
CTOR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CTOR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CTOR vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
CTOR$0.77$6.00+683.29%Strong Buy
ASRT$12.50$35.00+180.00%Buy
CPIX$3.01N/AN/A
CRDL$1.05$9.00+757.14%Buy
RMTI$1.06$2.50+135.85%Buy
View Top Pharmaceutical Stocks

Citius Oncology Stock Forecast FAQ

Is Citius Oncology Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CTOR) stock is to Strong Buy CTOR stock.

Out of 1 analyst, 1 (100%) are recommending CTOR as a Strong Buy, 0 (0%) are recommending CTOR as a Buy, 0 (0%) are recommending CTOR as a Hold, 0 (0%) are recommending CTOR as a Sell, and 0 (0%) are recommending CTOR as a Strong Sell.

If you're new to stock investing, here's how to buy Citius Oncology stock.

What is CTOR's earnings growth forecast for 2026-2028?

(NASDAQ: CTOR) Citius Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 15.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 75.75%.

Citius Oncology's earnings in 2026 is -$23,636,233.On average, 3 Wall Street analysts forecast CTOR's earnings for 2026 to be -$17,107,735, with the lowest CTOR earnings forecast at -$16,436,843, and the highest CTOR earnings forecast at -$17,610,903. On average, 3 Wall Street analysts forecast CTOR's earnings for 2027 to be $35,115,876, with the lowest CTOR earnings forecast at $33,738,783, and the highest CTOR earnings forecast at $36,148,696.

In 2028, CTOR is forecast to generate $67,530,531 in earnings, with the lowest earnings forecast at $64,882,275 and the highest earnings forecast at $69,516,723.

What is CTOR's revenue growth forecast for 2026-2028?

(NASDAQ: CTOR) Citius Oncology's forecast annual revenue growth rate of 421.28% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 15.36%.

Citius Oncology's revenue in 2026 is $3,944,111.On average, 3 Wall Street analysts forecast CTOR's revenue for 2026 to be $3,499,935,288, with the lowest CTOR revenue forecast at $3,362,755,621, and the highest CTOR revenue forecast at $3,602,952,451. On average, 3 Wall Street analysts forecast CTOR's revenue for 2027 to be $10,709,547,749, with the lowest CTOR revenue forecast at $10,290,240,530, and the highest CTOR revenue forecast at $11,024,690,228.

In 2028, CTOR is forecast to generate $14,173,466,754 in revenue, with the lowest revenue forecast at $13,617,332,969 and the highest revenue forecast at $14,590,125,717.

What is CTOR's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: CTOR) forecast ROA is 61.41%, which is higher than the forecast US Drug Manufacturers - Specialty & Generic industry average of 17.28%.

What is CTOR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CTOR price target, the average CTOR price target is $6.00, with the highest CTOR stock price forecast at $6.00 and the lowest CTOR stock price forecast at $6.00.

The Wall Street analyst predicted that Citius Oncology's share price could reach $6.00 by Sep 23, 2026. The average Citius Oncology stock price prediction forecasts a potential upside of 683.29% from the current CTOR share price of $0.77.

What is CTOR's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CTOR) Citius Oncology's current Earnings Per Share (EPS) is -$0.31. On average, analysts forecast that CTOR's EPS will be -$0.19 for 2026, with the lowest EPS forecast at -$0.19, and the highest EPS forecast at -$0.20. On average, analysts forecast that CTOR's EPS will be $0.40 for 2027, with the lowest EPS forecast at $0.38, and the highest EPS forecast at $0.41. In 2028, CTOR's EPS is forecast to hit $0.77 (min: $0.74, max: $0.79).

What is CTOR's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: CTOR) forecast ROE is 115.61%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.